Who We Are

Who We Are

Overview

VLST Corporation is a privately held biotechnology company dedicated to the streamlined discovery and development of novel therapeutics for the treatment of inflammatory and autoimmune disorders.

Inset photo

The Company's proprietary technology platform allows for the efficient identification of high quality, validated drug targets based on a thorough understanding of virulence gene products and their function. Such an approach offers the opportunity to improve the prioritization of drug targets and reduce costs by improving the clinical success rate. The VLST discovery platform has primary applications for the treatment of rheumatoid arthritis, Crohn's disease, multiple sclerosis, lupus and vasculitis.

Formed in 2004, VLST includes preeminent scientific co-founders and a seasoned leadership team. VLST was co-founded by Dr. Craig Smith, who along with Dr. Ray Goodwin, a member of the VLST scientific advisory board, invented Enbrel®, a biologic therapy for the treatment of several inflammatory disorders.